Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease. Issue 1 (2nd May 2022)

• Record Type: Journal Article
• Authors: Furukawa, Koji; Shima, Atsushi; Kambe, Daisuke; Nishida, Akira; Wada, Ikko; Sakamaki, Haruhi; Yoshimura, Kenji; Terada, Yuta; Sakato, Yusuke; Mitsuhashi, Masahiro; Sawamura, Masanori; Nakanishi, Etsuro; Taruno, Yosuke; Yamakado, Hodaka; Fushimi, Yasutaka; Okada, Tomohisa; Nakamoto, Yuji; Takahashi, Ryosuke; Sawamoto, Nobukatsu
• Is Part Of: Annals of neurology. Volume 92:Issue 1(2022)
• Page Start: 110
• Page End: 121
• Publication Date: 2022-05-02
• Subjects: Neurology -- Periodicals; Pediatric neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 616.8
• DOI: 10.1002/ana.26373
• Languages: English
• ISSNs: 0364-5134

Abstract

Abstract : Objective: The motor severity in Parkinson disease (PD) is believed to parallel dopaminergic terminal degeneration in the striatum, although the terminal was reported to be virtually absent by 4 years postdiagnosis. Meanwhile, neuromelanin‐laden dopamine neuron loss in the substantia nigra (SN) elucidated a variability at early stages and gradual loss with less variability 10 years postdiagnosis. Here, we aimed to clarify the correlation between motor impairments and striatal dopaminergic terminal degeneration and nigral neuromelanin‐laden dopamine neuron loss at early to advanced stages of PD. Methods: Ninety‐three PD patients were divided into early and advanced subgroups based on motor symptom duration and whether motor fluctuation was present. Striatal dopaminergic terminal degeneration was evaluated using a presynaptic dopamine transporter tracer, 123 I‐ioflupane single photon emission computed tomography (SPECT). Nigral neuromelanin‐laden dopamine neuron density was assessed by neuromelanin‐sensitive magnetic resonance imaging (NM‐MRI). Results: In patients with early stage PD (motor symptoms for ≤8 or 10 years), motor dysfunction during the drug‐off state was paralleled by a decline in 123 I‐ioflupane uptake in the striatum despite the absence of a correlation with reductions in NM‐MRI signals in SN. Meanwhile, in patients with advanced stage PD (motor symptoms for >8 or 10 years and with fluctuation), the degree of motor deficits during the drug‐off state was not correlated with 123 I‐ioflupane uptake in the striatum, despite its significant negative correlation with NM‐MRI signals in SN. Interpretation: We propose striatal dopaminergic terminal loss measured using 123 I‐ioflupane SPECT and nigral dopamine neuron loss assessed with NM‐MRI as early stage and advanced stage motor impairment biomarkers, respectively. ANN NEUROL 2022;92:110–121